Takeaways: The acquisition turns Jamieson into Kirin’s North American foundation alongside Blackmores and FANCL, creating a multi‑brand global preventative health portfolio that can leverag...
Takeaways: GSK’s prefilled Shingrix syringe should improve operational convenience for clinics and pharmacies by removing the reconstitution step, which can reduce preparation time, ha...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
Takeaways: Kashiv BioSciences gets a key regulatory step for its XOLAIR (omalizumab) biosimilar, ADL-018. The market implication is a likely cost-reduction play in a high-value o...
Patient centricity has become one of the most widely used, and often overused, terms in the biopharma industry. In Canadian Health discussions, nearly every stakeholder references it in some form, emb...
The healthcare and biopharma industries are facing a growing talent crisis that threatens to slow innovation and place additional strain on already burdened systems. Within Canadian Health, workforce ...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
